Get Cash Back and $0 Commissions
+ The Power of TradeStation
PRNewswire 8-May-2018 7:00 AM
PR Newswire
LAVAL, Quebec, May 8, 2018
LAVAL, Quebec, May 8, 2018 /PRNewswire/ --
Valeant Pharmaceuticals International, Inc. (TSX:VRX) ("Valeant" or the "Company" or "we") today announced its first-quarter 2018 financial results.
"Our first-quarter 2018 results demonstrate that we are making significant progress in our turnaround. For the first time since 2015, the Company delivered overall organic revenue growth2 that tracked above expectations and was driven by our Branded Rx and Bausch + Lomb/International segments," said Joseph C. Papa, chairman and CEO, Valeant. "As a result, we are raising our full-year revenue and Adjusted EBITDA (non-GAAP) guidance ranges to reflect our strong performance in the first quarter."
Company Highlights
Executing on Core Businesses and Advancing Pipeline
Reducing Debt and Extending Maturities
Resolving Legal Issues
First-Quarter 2018 Revenue Performance
Total reported revenues were $1.995 billion for the first quarter of 2018, as compared to $2.109 billion in the first quarter of 2017, a decrease of $114 million, or 5%. Excluding the impact of the 2017 divestitures and discontinuations of $214 million and the favorable impact of foreign exchange of $66 million, revenue grew organically2 by 2% compared to the first quarter of 2017, primarily driven by growth in the Salix business and the Bausch + Lomb/International segment. Organic2 revenue growth was partially offset by declines in the Ortho Dermatologics business and lower volumes in the U.S. Diversified Products segment, attributed to the previously reported loss of exclusivity for a basket of products.
Revenues by segment for the first quarter of 2018 were as follows:
(in millions) |
1Q 2018 |
1Q 20174 |
Reported |
Reported |
Change at |
Organic2 Change |
|||||||
Segment |
|||||||||||||
Bausch + Lomb/International |
$1,103 |
$1,134 |
($31) |
(3%) |
(8%) |
2% |
|||||||
Branded Rx |
$593 |
$629 |
($36) |
(6%) |
(6%) |
8% |
|||||||
U.S. Diversified Products |
$299 |
$346 |
($47) |
(14%) |
(14%) |
(9%) |
|||||||
Total Revenues |
$1,995 |
$2,109 |
($114) |
(5%) |
(9%) |
2% |
Bausch + Lomb/International Segment
Bausch + Lomb/International segment revenues were $1.103 billion for the first quarter of 2018, as compared to $1.134 billion for the first quarter of 2017, a decrease of $31 million, or 3%. Excluding the impact of divestitures and discontinuations of $113 million, and the favorable impact of foreign exchange of $65 million, the Bausch + Lomb/International segment grew organically2 by approximately 2% compared to the first quarter of 2017.
Branded Rx Segment
Branded Rx segment revenues were $593 million for the first quarter of 2018, as compared to $629 million for the first quarter of 2017, a decrease of $36 million, or 6%. Excluding the impact of divestitures and discontinuations of $83 million and the favorable impact of foreign exchange of $1 million, the Branded Rx segment grew organically2 by approximately 8% compared to the first quarter of 2017. Compared to the first quarter of 2017, the Salix business grew revenue by 40%, largely driven by sales growth in XIFAXAN® and other promoted products.
U.S. Diversified Products Segment
U.S. Diversified Products segment revenues were $299 million for the first quarter of 2018, as compared to $346 million for the first quarter of 2017, a decrease of $47 million, or 14%. The decline was primarily driven by decreases attributed to the previously reported loss of exclusivity for a basket of products and by the impact of the 2017 divestitures and discontinuations of $18 million.
Operating Loss
Operating loss was $2.281 billion for the first quarter of 2018, as compared to an operating income of $211 million for the first quarter of 2017, a decrease of $2.492 billion. The decrease in operating results for the first quarter of 2018 primarily reflects goodwill impairment charges of $2.213 billion related to the Salix and Ortho Dermatologics businesses. These charges were recognized when the Company adopted new accounting guidance from the Financial Accounting Standards Board in January 2018.
Net Loss
Net loss for the three months ended March 31, 2018 was $2.693 billion, as compared to net income of $628 million for the same period in 2017, a decrease of $3.321 billion. The decrease in net income is primarily attributed to a decrease in the benefit from income taxes and the goodwill impairment charges recorded in the first quarter of 2018. Net income in the first quarter of 2017 included an income tax benefit of $908 million from a non-cash internal restructuring in that quarter.
Adjusted net income (non-GAAP) for the first quarter of 2018 was $312 million, as compared to $273 million for the first quarter of 2017, an increase of 14%.
Operating Cash
The Company delivered $438 million in operating cash in the first quarter of 2018, which was above expectations due to reductions in working capital and despite settlement payments of $170 million that were made in the first quarter for certain legacy legal matters, including the SOLODYN® Antitrust Class Actions and Allergan Shareholder Class Actions.
Cash flow in the first quarter of 2018 decreased by $516 million, as compared to $954 million in the first quarter of 2017. The first quarter of 2017 included a one-time cash receipt attributed to our fulfillment agreement with Walgreens.
EPS
GAAP Earnings Per Share (EPS) Diluted for the first quarter of 2018 was $(7.68), as compared to $1.79 for the first quarter of 2017.
Adjusted EBITDA (non-GAAP)
Adjusted EBITDA (non-GAAP) was $832 million for the first quarter of 2018, as compared to $861 million for the first quarter of 2017, a decrease of $29 million, primarily driven by the impact of the 2017 divestitures of $75 million, offset by growth in the Salix business.
2018 Financial Outlook
Valeant has raised guidance for the full year of 2018 and has not changed anticipated dates for products losing exclusivity (LOE) later this year:
Other than with respect to GAAP Revenues, the Company only provides guidance on a non-GAAP basis. The Company does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP) to GAAP net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. In periods where significant acquisitions or divestitures are not expected, the Company believes it might have a basis for forecasting the GAAP equivalent for certain costs, such as amortization, which would otherwise be treated as non-GAAP to calculate projected GAAP net income (loss). However, because other deductions (such as restructuring, gain or loss on extinguishment of debt and litigation and other matters) used to calculate projected net income (loss) vary dramatically based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income (loss) at this time. The amount of these deductions may be material and, therefore, could result in projected GAAP net income (loss) being materially less than projected Adjusted EBITDA (non-GAAP). The guidance provided in this section represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Forward-looking Statements section of this news release.
Additional Highlights
Conference Call Details
Date: |
Tuesday, May 8, 2018 |
Time: |
8:00 a.m. EDT |
Web cast: |
|
Participant Event Dial-in: |
(844) 428-3520 (North America) |
(409) 767-8386 (International) |
|
Participant Passcode: |
6185877 |
Replay Dial-in: |
(855) 859-2056 (North America) |
(404) 537-3406 (International) |
|
Replay Passcode: |
6185877 (replay available until July 8, 2018) |
About Valeant
Valeant Pharmaceuticals International, Inc. (TSX:VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.valeant.com.
Forward-looking Statements
This press release contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding Valeant's future prospects and performance including the Company's 2018 revised full-year guidance, the anticipated approval and launch dates for certain of our products, the anticipated timing of the commencement of studies for certain of our pipeline products, the anticipated timing of loss of exclusivity for certain of our products and the final court approval of the settlements of the Allergan securities litigation and SOLODYN® antitrust litigation. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," "tracking," or "continue" and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the Company's full-year guidance, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results and events to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements (including the Company's 2018 full-year guidance), including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements, and additional information regarding certain of these material factors and assumptions may also be found in the Company's filings described above. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
Non-GAAP Information
To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures including (i) Adjusted EBITDA (non-GAAP), (ii) organic growth and (iii) constant currency. As discussed below, we also provide Adjusted Net Income (non-GAAP) to provide supplemental information to readers. Management uses these non-GAAP measures as key metrics in the evaluation of company performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures are useful to investors in their assessment of our operating performance and the valuation of our Company. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors, and in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.
However, these measures are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to similar non-GAAP measures. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.
The reconciliations of these historic non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are shown in the tables below. However, as indicated above, for guidance purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations.
Specific Non-GAAP Measures
Adjusted EBITDA (non-GAAP)
Adjusted EBITDA (non-GAAP) is GAAP net income (its most directly comparable GAAP financial measure) adjusted for certain items, as further described below. Management of the Company believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives, especially in light of the Company's new strategies. In particular, the Company believes that Adjusted EBITDA (non-GAAP) focuses management on the Company's underlying operational results and business performance. As a result, the Company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, commencing in 2017, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.
Adjusted EBITDA (non-GAAP) reflect adjustments based on the following items:
Finally, to the extent not already adjusted for above, Adjusted EBITDA (non-GAAP) reflects adjustments for interest, taxes, depreciation and amortization (EBITDA represents earnings before interest, taxes, depreciation and amortization).
Adjusted Net Income (Loss) (non-GAAP)
Historically, management has used adjusted net income (loss) (non-GAAP) (the most directly comparable GAAP financial measure for which is GAAP net income (loss)) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as further described below) that may obscure trends in the Company's underlying performance. By disclosing this non-GAAP measure, it was management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. It was management's belief that this measure was also useful to investors as such measure allowed investors to evaluate the Company's performance using the same tools that management had used to evaluate past performance and prospects for future performance. Accordingly, it was the Company's belief that adjusted net income (loss) (non-GAAP) was useful to investors in their assessment of the Company's operating performance and the valuation of the Company. It is also noted that, in recent periods, our GAAP net income was significantly lower than our adjusted net income (non-GAAP). Commencing in 2017, management of the Company identified and began using certain new primary financial performance measures to assess the Company's financial performance. However, management still believes that adjusted net income (loss) (non-GAAP) may be useful to investors in their assessment of the Company and its performance.
In addition to certain of the adjustments described above (namely restructuring and integration costs, acquired in-process research and development costs, loss on extinguishment of debt, asset impairments, acquisition-related adjustments, excluding amortization, and other non-GAAP charges), adjusted net income (non-GAAP) also reflects adjustments based on the following additional items:
Organic Growth
Organic Growth, a non-GAAP metric, is defined as an increase on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations. Organic Growth is growth in GAAP Revenue (its most directly comparable GAAP financial measure) adjusted for certain items, as further described below, of businesses that have been owned for one or more years. The Company uses organic revenue and organic growth to assess performance of its business units and operating and reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as it provides a supplemental period-to-period comparison.
Organic revenue growth reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/ or discontinued. These adjustments are determined as follows:
Constant Currency
Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company's financial results and financial position. To assist investors in evaluating the Company's performance, we have adjusted for foreign currency effects. Constant currency impact is determined by comparing 2018 reported amounts adjusted to exclude currency impact, calculated using 2017 monthly average exchange rates, to the actual 2017 reported amounts.
Please also see the reconciliation tables below for further information as to how these non-GAAP measures are calculated for the periods presented.
1 |
Please see the tables at the end of this news release for a reconciliation of this and other non-GAAP measures to the nearest comparable GAAP measure. |
||||||||
2 |
Organic growth, a non-GAAP metric, is defined as an increase on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations. |
||||||||
3 |
Provisional name |
||||||||
4 |
Effective in the first quarter of 2018, revenues from the U.S. Solta business included in the U.S. Diversified Products segment in prior periods and revenues from the international Solta business included in the Bausch + Lomb/International segment in prior periods are presented in the Branded Rx segment. Prior period presentations of segment revenues have been conformed to the current segment reporting structure to allow investors to evaluate results between periods on a constant basis. Global Solta revenue was $29 million and $23 million for the first quarters of 2018 and 2017, respectively. |
||||||||
5 |
To assist investors in evaluating the Company's performance, we have adjusted for changes in foreign currency exchange rates. Change at constant currency, a non-GAAP metric, is determined by comparing 2018 reported amounts adjusted to exclude currency impact, calculated using 2017 monthly average exchange rates, to the actual 2017 reported amounts. |
FINANCIAL TABLES FOLLOW
Valeant Pharmaceuticals International, Inc. |
Table 1 |
|||||||
Condensed Consolidated Statements of Operations |
||||||||
For the Three Months Ended March 31, 2018 and 2017 |
||||||||
(unaudited) |
||||||||
Three Months Ended |
||||||||
March 31, |
||||||||
(in millions) |
2018 |
2017 |
||||||
Revenues |
||||||||
Product sales |
$ |
1,965 |
$ |
2,076 |
||||
Other revenues |
30 |
33 |
||||||
1,995 |
2,109 |
|||||||
Expenses |
||||||||
Cost of goods sold (exclusive of amortization and impairments of intangible assets) |
560 |
584 |
||||||
Cost of other revenues |
13 |
12 |
||||||
Selling, general and administrative |
591 |
661 |
||||||
Research and development |
92 |
96 |
||||||
Amortization of intangible assets |
743 |
635 |
||||||
Goodwill impairments |
2,213 |
— |
||||||
Asset impairments |
44 |
138 |
||||||
Restructuring and integration costs |
6 |
18 |
||||||
Acquired in-process research and development costs |
1 |
4 |
||||||
Acquisition-related contingent consideration |
2 |
(10) |
||||||
Other expense (income), net |
11 |
(240) |
||||||
4,276 |
1,898 |
|||||||
Operating (loss) income |
(2,281) |
211 |
||||||
Interest income |
3 |
3 |
||||||
Interest expense |
(416) |
(474) |
||||||
Loss on extinguishment of debt |
(27) |
(64) |
||||||
Foreign exchange and other |
27 |
29 |
||||||
Loss before benefit from income taxes |
(2,694) |
(295) |
||||||
Benefit from income taxes |
(3) |
(924) |
||||||
Net (loss) income |
(2,691) |
629 |
||||||
Less: Net income attributable to noncontrolling interest |
2 |
1 |
||||||
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc. |
$ |
(2,693) |
$ |
628 |
Valeant Pharmaceuticals International, Inc. |
Table 2 |
|||||||
Reconciliation of GAAP Net (Loss) Income to Adjusted Net Income (non-GAAP) |
||||||||
For the Three Months Ended March 31, 2018 and 2017 |
||||||||
(unaudited) |
||||||||
Three Months Ended |
||||||||
March 31, |
||||||||
(in millions) |
2018 |
2017 |
||||||
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc. |
$ |
(2,693) |
$ |
628 |
||||
Non-GAAP adjustments: (a) |
||||||||
Amortization of intangible assets |
743 |
635 |
||||||
Asset impairments |
44 |
138 |
||||||
Goodwill impairments |
2,213 |
— |
||||||
Restructuring and integration costs |
6 |
18 |
||||||
Acquired in-process research and development costs |
1 |
4 |
||||||
Acquisition-related adjustments excluding amortization of intangible assets |
2 |
(10) |
||||||
Loss on extinguishment of debt |
27 |
64 |
||||||
Legal and other professional fees |
5 |
10 |
||||||
Litigation and other matters |
11 |
77 |
||||||
Net gain on sale of assets |
— |
(317) |
||||||
Other |
(1) |
— |
||||||
Tax effect of non-GAAP adjustments |
(46) |
(974) |
||||||
Total non-GAAP adjustments |
3,005 |
(355) |
||||||
Adjusted net income attributable to Valeant Pharmaceuticals International, Inc. (non-GAAP) |
$ |
312 |
$ |
273 |
||||
(a) |
The components of (and further details respecting) each of these non-GAAP adjustments and the financial statement line item to which each component relates can be found on Table 2a. |
Valeant Pharmaceuticals International, Inc. |
Table 2a |
|||||||
Reconciliation of GAAP to Non-GAAP Financial Information |
||||||||
For the Three Months Ended March 31, 2018 and 2017 |
||||||||
(unaudited) |
||||||||
Three Months Ended |
||||||||
March 31, |
||||||||
(in millions) |
2018 |
2017 |
||||||
Selling, general and administrative reconciliation: |
||||||||
GAAP Selling, general and administrative |
$ |
591 |
$ |
661 |
||||
Legal and other professional fees (a) |
(5) |
(10) |
||||||
Other Selling, general and administrative (b) |
1 |
— |
||||||
Adjusted selling, general and administrative (non-GAAP) |
$ |
587 |
$ |
651 |
||||
Amortization of intangible assets reconciliation: |
||||||||
GAAP Amortization of intangible assets |
$ |
743 |
$ |
635 |
||||
Amortization of intangible assets (c) |
(743) |
(635) |
||||||
Adjusted amortization of intangible assets (non-GAAP) |
$ |
— |
$ |
— |
||||
Goodwill impairment reconciliation: |
||||||||
GAAP Goodwill impairment |
$ |
2,213 |
$ |
— |
||||
Goodwill impairment (d) |
(2,213) |
— |
||||||
Adjusted goodwill impairment (non-GAAP) |
$ |
— |
$ |
— |
||||
Restructuring and integration costs reconciliation: |
||||||||
GAAP Restructuring and integration costs |
$ |
6 |
$ |
18 |
||||
Restructuring and integration costs (e) |
(6) |
(18) |
||||||
Adjusted restructuring and integration costs (non-GAAP) |
$ |
— |
$ |
— |
||||
Acquired in-process research and development costs reconciliation: |
||||||||
GAAP Acquired in-process research and development costs |
$ |
1 |
$ |
4 |
||||
Acquired in-process research and development costs (f) |
(1) |
(4) |
||||||
Adjusted acquired in-process research and development costs (non-GAAP) |
$ |
— |
$ |
— |
||||
Asset impairments reconciliation: |
||||||||
GAAP Asset impairments |
$ |
44 |
$ |
138 |
||||
Asset impairments (g) |
(44) |
(138) |
||||||
Adjusted asset impairments (non-GAAP) |
$ |
— |
$ |
— |
||||
Acquisition-related contingent consideration reconciliation: |
||||||||
GAAP Acquisition-related contingent consideration |
$ |
2 |
$ |
(10) |
||||
Acquisition-related contingent consideration (h) |
(2) |
10 |
||||||
Adjusted acquisition-related contingent consideration (non-GAAP) |
$ |
— |
$ |
— |
||||
Other expense (income), net reconciliation: |
||||||||
GAAP Other expense (income), net |
$ |
11 |
$ |
(240) |
||||
Litigation and other matters (i) |
(11) |
(77) |
||||||
Net gain on sale of assets (j) |
— |
317 |
||||||
Adjusted other expense (income) (non-GAAP) |
$ |
— |
$ |
— |
||||
Loss on extinguishment of debt reconciliation: |
||||||||
GAAP Loss on extinguishment of debt |
$ |
(27) |
$ |
(64) |
||||
Loss on extinguishment of debt (k) |
27 |
64 |
||||||
Adjusted loss on extinguishment of debt (non-GAAP) |
$ |
— |
$ |
— |
||||
Table 2a (continued) |
||||||||
Three Months Ended |
||||||||
March 31, |
||||||||
(in millions) |
2018 |
2017 |
||||||
Benefit from income taxes reconciliation: |
||||||||
GAAP Benefit from income taxes |
$ |
(3) |
$ |
(924) |
||||
Tax effect of non-GAAP adjustments (l) |
46 |
974 |
||||||
Adjusted provision for income taxes (non-GAAP) |
$ |
43 |
$ |
50 |
||||
(a) |
Represents the sole component of the non-GAAP adjustment of "Legal and other professional fees" (see Table 2). Legal and other professional fees incurred during the three months ended March 31, 2018 and 2017 in connection with recent legal and governmental proceedings, investigations and information requests related to, among other matters, our distribution, marketing, pricing, disclosure and accounting practices. |
||||||||
(b) |
Represents the sole component of the non-GAAP adjustment of "Other" (see Table 2). |
||||||||
(c) |
Represents the sole component of the non-GAAP adjustment of "Amortization of intangible assets" (see Table 2). |
||||||||
(d) |
Represents the sole component of the non-GAAP adjustment of "Goodwill impairment" (see Table 2). |
||||||||
(e) |
Represents the sole component of the non-GAAP adjustment of "Restructuring and integration costs" (see Table 2). |
||||||||
(f) |
Represents the sole component of the non-GAAP adjustment of "Acquired in-process research and development costs" (see Table 2). |
||||||||
(g) |
Represents the sole component of the non-GAAP adjustment of "Asset impairments" (see Table 2). |
||||||||
(h) |
Represents the sole component of the non-GAAP adjustment of "Acquisition-related adjustments excluding amortization of intangible assets" (see Table 2). |
||||||||
(i) |
Represents the sole component of the non-GAAP adjustment of "Litigation and other matters" (see Table 2). |
||||||||
(j) |
Represents the sole component of the non-GAAP adjustment "Net gain on sale of assets" (see Table 2). Net gain on sale of assets of $317 million during the three months ended March 31, 2017 includes the $319 million gain on the sale of CeraVe, AcneFree and AMBI skincare brands in March of 2017. |
||||||||
(k) |
Represents the sole component of the non-GAAP adjustment of "Loss on extinguishment of debt" (see Table 2). |
||||||||
(l) |
Represents the sole component of the non-GAAP adjustment of "Tax effect of non-GAAP adjustments" (see Table 2). |
Valeant Pharmaceuticals International, Inc. |
Table 2b |
||||||||
Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA (non-GAAP) |
|||||||||
For the Three Months Ended March 31, 2018 and 2017 |
|||||||||
(unaudited) |
|||||||||
Three Months Ended |
|||||||||
March 31, |
|||||||||
(in millions) |
2018 |
2017 |
|||||||
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc. |
$ |
(2,693) |
$ |
628 |
|||||
Interest expense, net |
413 |
471 |
|||||||
Benefit from income taxes |
(3) |
(924) |
|||||||
Depreciation and amortization |
786 |
674 |
|||||||
EBITDA |
(1,497) |
849 |
|||||||
Adjustments: |
|||||||||
Asset impairments |
44 |
138 |
|||||||
Goodwill impairments |
2,213 |
— |
|||||||
Restructuring and integration costs |
6 |
18 |
|||||||
Acquired in-process research and development costs |
1 |
4 |
|||||||
Acquisition-related adjustments excluding amortization and depreciation |
2 |
(10) |
|||||||
Loss on extinguishment of debt |
27 |
64 |
|||||||
Share-based compensation |
21 |
28 |
|||||||
Other adjustments: |
|||||||||
Legal and other professional fees (a) |
5 |
10 |
|||||||
Litigation and other matters |
11 |
77 |
|||||||
Net gain on sale of assets (b) |
— |
(317) |
|||||||
Other |
(1) |
— |
|||||||
Adjusted EBITDA (non-GAAP) |
$ |
832 |
$ |
861 |
|||||
(a) |
Legal and other professional fees incurred during the three months ended March 31, 2018 and 2017 in connection with recent legal and governmental proceedings, investigations and information requests related to, among other matters, our distribution, marketing, pricing, disclosure and accounting practices. |
|||||||||
(b) |
Net gain on sale of assets of $317 million during the three months ended March 31, 2017 includes the $319 million gain on the sale of CeraVe, AcneFree and AMBI skincare brands in March of 2017. |
Valeant Pharmaceuticals International, Inc. |
Table 3 |
|||||||||||||||||||||||||||||
Organic Growth (non-GAAP) - by Segment |
||||||||||||||||||||||||||||||
For the Three Months Ended March 31, 2018 and 2017 |
||||||||||||||||||||||||||||||
(unaudited) |
||||||||||||||||||||||||||||||
Calculation of Organic Revenue |
||||||||||||||||||||||||||||||
Three Months Ended March 31, 2018 |
Three Months Ended March 31, 2017 |
Change in Organic |
||||||||||||||||||||||||||||
Revenue as Reported |
Changes |
Organic |
Revenue as Reported |
Divested |
Organic |
|||||||||||||||||||||||||
(in millions) |
Amount |
Pct. |
||||||||||||||||||||||||||||
Bausch + Lomb/International |
||||||||||||||||||||||||||||||
Global Vision Care |
$ |
195 |
$ |
(10) |
$ |
185 |
$ |
170 |
$ |
— |
$ |
170 |
$ |
15 |
9% |
|||||||||||||||
Global Surgical (c) |
171 |
(12) |
159 |
154 |
(1) |
153 |
6 |
4% |
||||||||||||||||||||||
Global Consumer Products |
330 |
(17) |
313 |
375 |
(63) |
312 |
1 |
—% |
||||||||||||||||||||||
Global Ophtho Rx |
143 |
(5) |
138 |
143 |
— |
143 |
(5) |
(3)% |
||||||||||||||||||||||
International Rx (c)(d) |
264 |
(21) |
243 |
292 |
(49) |
243 |
— |
—% |
||||||||||||||||||||||
Total Bausch + Lomb/International (e) |
1,103 |
(65) |
1,038 |
1,134 |
(113) |
1,021 |
17 |
2% |
||||||||||||||||||||||
Branded Rx |
||||||||||||||||||||||||||||||
Salix |
422 |
— |
422 |
302 |
— |
302 |
120 |
40% |
||||||||||||||||||||||
Ortho Dermatologics (f) |
112 |
— |
112 |
194 |
— |
194 |
(82) |
(42)% |
||||||||||||||||||||||
Global Solta (d) |
29 |
(1) |
28 |
23 |
— |
23 |
5 |
18% |
||||||||||||||||||||||
Dentistry |
30 |
— |
30 |
28 |
(1) |
27 |
3 |
11% |
||||||||||||||||||||||
Other revenues |
— |
— |
— |
82 |
(82) |
— |
— |
— |
||||||||||||||||||||||
Total Branded Rx |
593 |
(1) |
592 |
629 |
(83) |
546 |
46 |
8% |
||||||||||||||||||||||
U.S. Diversified Products (d) |
||||||||||||||||||||||||||||||
Neuro & Other |
209 |
— |
209 |
243 |
— |
243 |
(34) |
(14)% |
||||||||||||||||||||||
Generics |
90 |
— |
90 |
85 |
— |
85 |
5 |
6% |
||||||||||||||||||||||
Other revenues (f) |
— |
— |
— |
18 |
(18) |
— |
— |
— |
||||||||||||||||||||||
Total U.S. Diversified Products |
299 |
— |
299 |
346 |
(18) |
328 |
(29) |
(9)% |
||||||||||||||||||||||
Total revenues |
$ |
1,995 |
$ |
(66) |
$ |
1,929 |
$ |
2,109 |
$ |
(214) |
$ |
1,895 |
$ |
34 |
2% |
|||||||||||||||
(a) |
The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency |
||||||||||||||||||||||||||||||
(b) |
To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures. For additional information about the Company's use of such non-GAAP financial measures, refer to the body of the press release to which these tables are attached. Organic revenue (non-GAAP) for the three months ended March 31, 2018 is calculated as revenue as reported adjusted for the impact for changes in exchange rates (previously defined in this press release). Organic revenue (non-GAAP) for the three months ended March 31, 2017 is calculated as revenue as reported less revenues attributable to divestitures and discontinuances during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. Organic revenue is also adjusted for acquisitions, however, during the three months ended March 31, 2018 and 2017, there were no acquisitions. |
||||||||||||||||||||||||||||||
(c) |
As of the third quarter of 2017, one product has been removed from the Global Surgical business unit and added to the International Rx business unit. This change has been made as management believes that the product better aligns with the International Rx business unit, as this product, although acquired as part of the acquisition of certain surgical assets, is an injectable product. Prior period presentations of business unit revenue have been conformed to the current business unit reporting structure to allow investors to evaluate results between period on a consistent basis. |
||||||||||||||||||||||||||||||
Valeant Pharmaceuticals International, Inc. Table 3 (continued) |
|||||||||||||||||||||||||||||||
Organic Growth (non-GAAP) - by Segment |
|||||||||||||||||||||||||||||||
For the Three Months Ended March 31, 2018 and 2017 |
|||||||||||||||||||||||||||||||
(unaudited) |
|||||||||||||||||||||||||||||||
(d) |
Effective in the first quarter of 2018, revenues from the U.S. Solta business originally included as a separate business in the U.S. Diversified segment in prior periods and revenues from the international Solta business originally included in the International Rx business in the Bausch + Lomb/International segment in prior periods, are presented in the Branded Rx segment. Prior period presentations of segment revenues have been conformed to the current reporting structure to allow investors to evaluate results between period on a consistent basis. |
||||||||||||||||||||||||||||||
(e) |
Includes China organic growth as follows: |
Calculation of Organic Revenue |
|||||||||||||||||||||||||||||||
Three Months Ended March 31, 2018 |
Three Months Ended March 31, 2017 |
Change in |
|||||||||||||||||||||||||||||
Revenue as Reported |
Changes |
Organic |
Revenue as Reported |
Divested |
Organic |
||||||||||||||||||||||||||
(in millions) |
Amount |
Pct. |
|||||||||||||||||||||||||||||
China |
$ |
84 |
$ |
(6) |
$ |
78 |
$ |
68 |
$ |
(1) |
$ |
67 |
$ |
11 |
15% |
(f) |
Beginning in 2018, two products historically included in the reported results of the Other business unit in the U.S. Diversified segment will be included in the reported results of the Ortho Dermatologics business unit in the Branded Rx segment in all current and future periods, as management believes the products better align with that business unit. Revenues related to these products for three months ended March 31, 2017 were $2 million. Prior period presentations of segment and business unit revenues have been conformed to current segment and business unit reporting structures to allow investors to evaluate results between periods on a consistent basis. |
Valeant Pharmaceuticals International, Inc. |
Table 4 |
||||||||
Consolidated Balance Sheet and Other Financial Information |
|||||||||
(unaudited) |
|||||||||
(in millions) |
March 31, |
December 31, |
|||||||
Cash Balances |
|||||||||
Cash and cash equivalents |
$ |
909 |
$ |
720 |
|||||
Restricted cash |
— |
77 |
|||||||
Cash, cash equivalents and restricted cash |
$ |
909 |
$ |
797 |
|||||
Debt Balances |
|||||||||
Senior Secured Credit Facilities: |
|||||||||
Revolving Credit Facility |
$ |
250 |
$ |
250 |
|||||
Series F Tranche B Term Loan Facility |
3,225 |
3,420 |
|||||||
Senior Secured Notes |
4,941 |
4,939 |
|||||||
Senior Unsecured Notes: |
|||||||||
5.375% Senior Unsecured Notes due March 2020 |
688 |
1,699 |
|||||||
7.00% Senior Unsecured Notes due October 2020 |
— |
71 |
|||||||
6.375% Senior Unsecured Notes due October 2020 |
294 |
656 |
|||||||
9.25% Senior Unsecured Notes due 2026 |
1,480 |
— |
|||||||
All other Senior Unsecured Notes |
14,376 |
14,394 |
|||||||
Other |
14 |
15 |
|||||||
Total long-term debt, net of unamortized discounts and issuance costs |
25,268 |
25,444 |
|||||||
Plus: Unamortized discounts and issuance costs |
299 |
308 |
|||||||
Maturities of debt |
$ |
25,567 |
$ |
25,752 |
|||||
Maturities of Debt |
|||||||||
Remainder of 2018 |
$ |
2 |
$ |
209 |
|||||
2019 |
— |
— |
|||||||
2020 |
1,237 |
2,690 |
|||||||
2021 |
3,103 |
3,175 |
|||||||
2022 |
5,115 |
5,115 |
|||||||
2023 |
6,098 |
6,051 |
|||||||
Thereafter |
10,012 |
8,512 |
|||||||
Maturities of debt |
$ |
25,567 |
$ |
25,752 |
|||||
2018 |
2017 |
||||||||
Cash provided by operating activities - Three months ended March 31 |
$ |
438 |
$ |
954 |
Investor Contact: |
Media Contact: |
Arthur Shannon |
Lainie Keller |
(514) 856-3855 |
(908) 927-0617 |
(877) 281-6642 (toll free) |
View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-announces-first-quarter-2018-results-and-raises-revenue-and-adjusted-ebitda-non-gaap-guidance-300644146.html
SOURCE Valeant Pharmaceuticals International, Inc.